We are live on ! Find out more
ATRA icon

Atara Biotherapeutics
ATRA

84 hedge funds and large institutions have $493M invested in Atara Biotherapeutics in 2017 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 21 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more call options, than puts

Call options by funds: $540K | Put options by funds: $261K

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

49% more capital invested

Capital invested by funds: $330M → $493M (+$163M)

48% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 21

0.08% more ownership

Funds ownership: 3.22% → 3.3% (+0.08%)

1% less funds holding

Funds holding: 85 → 84 (-1)

Holders
84
Holders Change
-1
Holders Change %
-1.18%
% of All Funds
2.09%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
12
Increased
31
Reduced
21
Closed
8
Calls
$540K
Puts
$261K
Net Calls
+$279K
Net Calls Change
+$279K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$28.4M
2
BM
Bridger Management
New York
+$10.1M
3
RI
RTW Investments
New York
+$8.88M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$6.14M
5
EC
EcoR1 Capital
California
+$3.63M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$13.5M
2
UBS AM
UBS AM
Illinois
-$6.75M
3
SPC
Slate Path Capital
New York
-$6.75M
4
TA
Teachers Advisors
New York
-$1.51M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
76
Royal Bank of Canada
Ontario, Canada
$22K -$1.66K -4 -8%
MAM
77
Meeder Asset Management
Ohio
$10K +$828 +2 +11%
CHP
78
Cable Hill Partners
Oregon
$9K -$414 -1 -6%
Citigroup
79
Citigroup
New York
$5K -$727K -1,756 -99%
AG
80
Advisor Group
Arizona
$4K – – –
KF
81
Krilogy Financial
Missouri
$3K – – –
BNP Paribas Financial Markets
82
BNP Paribas Financial Markets
France
$2.71K -$19.5K -47 -90%
LTFS
83
Ladenburg Thalmann Financial Services
Florida
$1K – – –
UBS AM
84
UBS AM
Illinois
– -$6.75M -19,007 Closed
SPC
85
Slate Path Capital
New York
– -$6.75M -19,000 Closed
Susquehanna International Group
86
Susquehanna International Group
Pennsylvania
– -$305K -737 Closed
CIA
87
Capital Impact Advisors
Massachusetts
– -$199K -560 Closed
Squarepoint
88
Squarepoint
New York
– -$145K -407 Closed
DPA
89
Delphi Private Advisors
California
– -$121K -340 Closed
UBS Group
90
UBS Group
Switzerland
– -$139K -336 -100%
TRCT
91
Tower Research Capital (TRC)
New York
– -$8K -22 Closed
BBHC
92
Brown Brothers Harriman & Co
New York
– -$2K -5 Closed
1 2 3
4

ATRA Hedge Fund Activity: Q1 2017 in Review

84 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q1 2017, worth a combined $493M — up 49% from $330M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ATRA positions and 8 closed out — a net gain of 4 holders — while 31 added to existing stakes and 21 trimmed.

The largest buyer was BlackRock, adding an estimated $28.4M. The largest seller was Fidelity Investments, cutting an estimated $13.5M.

  • 84 institutional investors held Atara Biotherapeutics (ATRA) as of Q1 2017, down from 85 in Q4 2016.
  • Funds reported $493M of Atara Biotherapeutics stock for Q1 2017, up 49% quarter-over-quarter.
  • 12 funds opened new Atara Biotherapeutics positions in Q1 2017 and 8 closed out, a net change of +4 holders.
  • The largest Atara Biotherapeutics buyer in Q1 2017 was BlackRock, an estimated $28.4M added.
  • The largest Atara Biotherapeutics seller in Q1 2017 was Fidelity Investments, an estimated $13.5M sold.

Based on aggregated 13F filings for Q1 2017.